Morgan Stanley raised the target price for Hepalink (09989) to HKD3.7 from HKD3.3 and maintained the "equal-weight" rating.
The research house said following a 1H24 preliminary disclosure, it raises 2024-2030 earnings estimates by 11-14% on higher gross margins and investment income from the disposal of a stake in HighTide Therapeutics (2024 only).
【你點睇】烏軍攻入俄國庫爾斯克州近兩周,並炸毀兩座重要橋樑,你認為俄烏戰爭會否急劇惡化?► 立即投票